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1.  Introduction
Chan Su is a traditional Chinese medicine prepared 
from venenum bufonis, the dried white Secratio 
of the auricular and skin glands of toads, which 
has been used as an oriental drug for the treat-
ment of a number of diseases, including cancer 
[1]. In several previous reports, Chan Su has been 
shown to be potent in the treatment of various 
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cancer cells in vitro by induction of cell cycle ar-
rest and apoptosis [2−9]. Chan Su has been re-
ported to significantly induce apoptosis in human 
bladder car cinoma cells. This process was medi-
ated by an increase in Bax expression, decrease in 
Bcl-2 expression and a proteolytic activation of 
caspase-3 and caspase-9 [10].
The in vitro apoptotic effect of Venenum 
Bufonis venom has also been reported in the A549 
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cell line obtained from human lung carcinoma. In 
this study, SVB-induced-apoptosis was accompa-
nied by modulation of the death receptor system, 
Bcl-2 family members, mitochondrial dysfunction 
and activation of caspases [11]. Based on these re-
sults, we decided to investigate the antitumor ef-
fect of SVB in an animal model. The present study 
attempts to evaluate the antitumor activity of SVB 
in a NCI-H460 human lung carcinoma cell, in vivo, 
nude mouse xenograft model.
2.  Materials and Methods
2.1.  Cell line, culture conditions and SVB 
treatment
NCI-H460 cells were obtained from the Korean Cell 
Line Bank (Seoul, Korea). The cells were grown in 
RPMI-1640 medium supplemented with 10% fetal 
bovine serum, 100 U/mL penicillin and 100 mg/mL 
streptomycin. The SVB was obtained from Dunsan 
Oriental Hospital (Daejeon, South Korea). One hun-
dred grams of SVB was washed with distilled water, 
and then boiled in 1 L of water at 80ºC for 2.5 hours. 
Solid particles and aggregates were removed by 
centrifugation at 3000g for 30 minutes and super-
natants were lyophilized. Finally, 21.7 g lyophilized 
SVB were obtained and used in this experiment. The 
lyophilized extract was stored at −20ºC until use.
2.2.  Experimental animals
BALB/c nude mice (male, 9−11 weeks, n = 25) 
weighing 21−25 g were purchased from Japan SLC, 
Inc (Shizuoka, Japan) and were housed under 
specific pathogen-free conditions according to 
the guidelines of Chungbuk National University 
Animal Care and Use Committee. The animal room 
was controlled for temperature (22ºC ± 2ºC), light 
(12-hour light/dark cycle) and humidity (50% ± 
10%). All laboratory feed pellets and beddings were 
autoclaved.
2.3.  Experimental design
The tumor regression model in nude mice has been 
successfully and commonly applied to evaluate anti-
tumor activity. Therefore, this model was used to 
evaluate suppression of solid tumors following SVB 
administration. When the tumor volume reached 
100 mm3, the nude mice with xenografted tumor 
frag ments were randomly distributed into four 
groups [positive control, oral SVB (0.25 mg/kg), in-
traperitoneal SVB (0.25 mg/kg), and intraperito-
neal (0.5 mg/kg)]. Seven mice were allocated to each 
group; SVB was administered daily for 4 weeks.
2.4.  Cell preparation
NCI-H460 cells were cultured in 260-mL tissue cul-
ture flasks in Eagle’s minimum essential medium 
containing 100 U/mL penicillin and 10% heat inacti-
vated fetal calf serum in an incubator with 95% air 
and 5% CO2 at 37ºC. When the cells reached conflu-
ency they were washed twice with Hank’s balanced 
salt solution (HBSS), trypsinized with 0.25% trypsin, 
and washed twice with fresh culture medium.
2.5.  Xenografts
Following cell preparation, NCI-H460 cells (1 × 106 
cells/mouse in 0.1 mL HBSS) were injected subcu-
taneously into the flank of mice using a 26-gauge 
needle. After 14−16 days of observation, a solid 
tumor mass was observed in three out of five mice 
inoculated with NCI-H460 cells. Tumor fragments 
were made to 27 mm3 (3 mm × 3 mm × 3 mm) with a 
knife, and xenografted into the flank of new mice 
using a trocar. The suppressive effect of anticancer 
agents on solid tumors was evaluated in a tumor-
regression model. In brief, from the day tumor vol-
ume reached 100 mm3, mice xenografted with a 
tumor fragment were orally or intraperitoneally 
administered SVB daily for 28 days.
2.6.  Changes in tumor volume
The changes in tumor mass were recorded twice a 
week following measurement with digital calipers. 
That is, the largest and smallest diameters were 
measured in each mouse, and the tumor volume 
(V) was estimated according to the formula
Vmean = (A × B2)/2
where V is the tumor volume in mm3, and A and B 
are the largest and smallest tumor diameters in 
mm, respectively. Based on the regression of tumor 
volume, the antitumor activities of treatment were 
expressed by inhibition rate (IR).
IR (%) = [(CV − TV)/TV] × 100
where CV and TV are tumor volumes in control 
(water) and treatment groups, respectively. Tumor 
weights were also measured on the final day after 
animals were sacrificed and tumors removed.
2.7.  Mean survival time and percent 
increase in life span
To compare the life span of mice xenografted with 
NCI-H460 tumor fragments, survival time was esti-
mated from the day tumor volume reached 100 mm3 
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as described previously, and percent increase in life 
span (ILS) was calculated according to the equation:
ILS (%) = [(T − C)/C] × 100,
where C and T are mean survival days of mice in 
control and treatment groups, respectively.
2.8.  Blood chemistry
Blood samples were centrifuged at 1400g at 4ºC 
for 10 minutes. The supernatant (serum) were 
used to determine aspartate aminotransferase and 
alanine aminotransferase levels in an automatic 
analyzer (7170; Hitachi Ltd., Tokyo, Japan).
2.9.  Statistical analysis
Data are presented as mean ± SD. Differences be-
tween the mean of control and treatment groups 
were analyzed using one-way analysis of variance 
followed by a Dunnett’s t test correction, paired 
t test, and linear regression analysis. Statistical 
significance was determined at the level of p < 0.05 
or p < 0.01.
3.  Results
3.1.  Tumor size
Treatment with oral (0.25 mg/kg) and intraperito-
neal (0.25 mg/kg and 0.5 mg/kg) SVB inhibited the 
growth of NCI-H460 cell-transplanted solid tumors 
compared with positive control (Figure 1). The 
mean tumor volume in the orally treated group 
(3980.16 mm3) was lower than that of the control 
group throughout the study period, with a value of 
4492.22 mm3. Also the intraperitoneal treated group 
(0.5 mg/kg SVB) also showed a reduced tumor vol-
ume compared to control (3525.81 mm3).
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Figure 1   Time-course of increasing tumor volume in 
NCI-H460 cell-bearing mice treated with skin of vene-
num bufonis (SVB). Mice xenografted with tumor frag-
ments were treated with SVB from the day when tumor 
mass reached 100 mm3 (n = 7 for each group).
3.2.  Tumor volume
IR (%) of each group is shown in Table 1. From day 8 
to day 28, each IR tended towards dose-dependency. 
For example at day 11, oral SVB (0.25 mg/kg; IR 
90.79%) was less than intraperitoneal SVB (0.25 mg/
kg; IR 85.96%), which in turn was less than intra-
peritoneal SVB (0.5 mg/kg; IR 53.11%).
3.3.  Final tumor weight and volume
Final tumor weights and volumes of each group 
are shown in Table 2. Tumor weight and volume of 
the positive control group (NCI-H460 only) were 
2.52 g ± 0.75 g and 4.67 cm3 ± 1.18 cm3 on the final 
day. Tumor weight and volume following oral admin-
istration of SVB (0.25 mg/kg) were 2.50 g ± 0.77 g 
and 5.38 cm3 ± 1.73 cm3. Tumor weight and volume 
of the intraperitoneal SVB (0.25 mg/kg) treatment 
group were 2.62 g ± 0.64 g and 5.61 cm3 ± 1.41 cm3, 
while tumor weight and volume of intraperitoneal 
SVB (0.5 mg/kg) treatment group was 2.45 g ± 1.21 g 
and 4.49 cm3 ± 1.63 cm3. Compared with the positive 
Table 1  Inhibition rate (IR) on tumor volume in NCI-H460 tumor-bearing mice*
Day 0 4 7 11 14 18 21 25 28
NCI-H460 cells 100 100 100 100 100 100 100 100 100
 alone
Oral SVB 100.19  90.45 87.88 90.79 82.61 85.88 85.16 88.12 88.60 
 (0.25 mg/kg)
Intraperitoneal SVB  106.96 91.95 86.25 85.96 86.27 86.43 80.56 94.38 93.76 
 (0.25 mg/kg)
Intraperitoneal SVB  89.74 92.49 57.04 53.11 42.08 31.07 42.54 46.04 78.49
 (0.5 mg/kg)
*All values expressed as percentages. SVB = skin of venenum bufonis.
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control group, tumor weight and volume of SVB 
treatment groups were decreased.
3.4.  Survival time and percent ILS
Mean survival time and percent increase in life 
span are shown in Table 3 and Figure 2. Mean sur-
vival time following administration of oral, low 
SVB (0.25 mg/kg) was extended to 20.71 days ± 2.61 
days with a 4.66% increase in ILS. ILS was in fact 
increased in a dose-dependent manner. High intra-
peritoneal SVB (0.5 mg/kg) treatment was signifi-
cantly different from the positive control (NCI-H460 
cell alone) group.
3.5.  Body weight and spleen weight
Absolute weight of the kidney, liver, spleen, heart and 
lung are shown Table 4. Treatment with intraperito-
neal SVB (0.5 mg/kg) caused a significant decrease in 
total body weight and spleen weight (p < 0.05).
3.6.  Histological examination of liver tissue
Light microscopic histopathological examination of 
liver tissue in mice treated with SVB did not show any 
specific lesions compared with liver tissue from the 
control, NCI-H460 cell-bearing mice (Figure 3).
3.7.  Blood chemistry
The results of blood analyses are outlined in Table 5. 
Biochemical blood analysis revealed no significant 
Table 2  Final day tumor weight and volume in NCI-H460 cell−xenografted mice
 
NCI-H460 cells alone
 Oral SVB Intraperitoneal SVB Intraperitoneal SVB
  (0.25 mg/kg) (0.25 mg/kg) (0.5 mg/kg)
Tumor weight (g) 2.52 ± 0.75 2.50 ± 0.77 2.62 ± 0.64 2.45 ± 1.21
Tumor volume (cm3) 4.67 ± 1.18 5.38 ± 1.73 5.61 ± 1.41 4.49 ± 1.63
SVB = skin of venenum bufonis.
Table 3   Percent increase in life span (ILS) in NCI-
H460 tumor-bearing mice
Treatment Mean survival time (d) ILS (%)
NCI-H460 18.29 ± 3.59 0
 cells alone
Oral SVB 20.71 ± 2.61  4.66
 (0.25 mg/kg)
Intraperitoneal SVB 22.33 ± 2.44 18.61
 (0.25 mg/kg)
Intraperitoneal SVB 21.38 ± 7.65 16.87
 (0.5 mg/kg)
SVB = skin of venenum bufonis.
changes in alkaline phosphatase, creatinine and 
aspartate transaminase levels. Phosphatase and 
urea nitrogen levels in blood were significantly re-
duced following oral SVB (0.25 mg/kg; p < 0.01). 
The blood levels of CA and ALT were also signifi-
cantly decreased following administration of intra-
peritoneal SVB (0.5 mg/kg; p < 0.05 and p < 0.01, 
respectively).
4.  Discussion
The aim of this study was to examine whether SVB 
demonstrated antitumor effects by inhibiting the 
growth of tumors in NCI-H460 cell-xenografted mice. 
Human tumor xenografts in immunodeficient ani-
mal models provide a means to evaluate potential 
antitumor drugs in preclinical studies and are ap-
plicable for many different types of human malig-
nancies [12].
Venenum bufonis has been used in traditional 
Chinese medicine for many years. Its main compo-
nents include bufalin, cinobufagin, resibufogenin, 
cinobufotoxin, cinobufotalin and cinobufotalidin 
[13]. Reported pharmacological effects of venenum 
bufonis include regional anesthesia and analgesia, 
cardiotonic and pressor effects, as well as anti-
inflammatory, antitumor, and anti-asthmatic actions 
Intraperitoneal SVB
0.5 mg/kg
Intraperitoneal SVB
0.25 mg/kg
Oral SVB
0.25 mg/kg
NCI-H460
cell alone
0 5 10 15 20 25 30 35
Day
Figure 2   Mean survival time in NCI-H460 cell-bearing 
mice treated with SVB. Mice treated with intraperito-
neal SVB 0.25 mg/kg showed the highest mean survival 
time compared to any other group. Results are shown as 
mean ± SD.
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Table 4   Weight of organs in NCI-H460 tumor-bearing mice on final day of study
Treatment
 Absolute organ weights (g)
 Body weight  Liver Spleen Heart 
NCI-H460 cells alone 26.64 ± 1.61 1.76 ± 0.07 0.33 ± 0.04 0.15 ± 0.01
Oral SVB 27.62 ± 2.34 1.72 ± 0.13 0.41 ± 0.07 0.16 ± 0.02
 (0.25 mg/kg)
Intraperitoneal SVB 27.94 ± 1.62 1.68 ± 0.09 0.46 ± 0.08 0.17 ± 0.02
 (0.25 mg/kg)
Intraperitoneal SVB 31.18 ± 2.02* 1.55 ± 0.22 0.19 ± 0.22* 0.17 ± 0.01
 (0.50 mg/kg)
Treatment
 Absolute organ weights (g)
 Kidney  Testis 
 Left Right Left Right
NCI-H460 cells alone 0.22 ± 0.06 0.21 ± 0.05 0.11 ± 0.06 0.11 ± 0.06
Oral SVB 0.24 ± 0.02 0.23 ± 0.02 0.09 ± 0.05 0.10 ± 0.01
 (0.25 mg/kg)
Intraperitoneal SVB 0.25 ± 0.04 0.24 ± 0.03 0.09 ± 0.01 0.09 ± 0.01
 (0.25 mg/kg)
Intraperitoneal SVB 0.27 ± 0.02 0.26 ± 0.02 0.09 ± 0.01 0.09 ± 0.01
 (0.50 mg/kg)
*Compared to positive control group (NCI-H460 cells alone), p < 0.05. SVB = skin of venenum bufonis.
A B
C D
Figure 3   Gross liver structure from NCI-H460 cell-bearing mice. (A) NCI-H460 cells alone (positive control). (B) Oral 
skin of venenum bufonis (SVB) (0.25 mg/kg). (C) Intraperitoneal SVB (0.25 mg/kg). (D) Intraperitoneal SVB (0.5 mg/kg). 
No significant differences in liver tissue were observed. (100×, scale bar = 100 μm)
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[14]. Moreover recent studies have shown that vene-
num bufonis has antitumor effects in several tumor 
cells [2−9,13,15]. Based on these findings, we ex-
pected it to also have an antitumor effect in the 
in vivo model used in this study.
We conducted an in vivo experiment where nude 
mice carried a NCI-H460 cell-xenografted tumor 
for 28 days. These mice were treated with oral or 
intraperitoneal SVB (0.25 mg/kg), or with a higher 
intraperitoneal dose (0.5 mg/kg). Time-dependence 
changes of tumor volume were measured using dig-
ital calipers, and the removed tumor volume was 
measured using a plethysmometer in the final day 
of experiments. We observed that all of the SVB 
treated mice had smaller tumors. For example, the 
higher the dose of SVB, the lower the IR seen on day 
11 of the experiment. Furthermore, tumor weight 
and volume in mice treated with the highest dose 
of SVB were the smallest in size. This may imply 
that SVB reduced tumor size at a higher dose, al-
though given that results were not identical, a di-
rect causal relationship cannot be established at 
this stage.
Mice with cancer usually lose weight due to 
cachexia. In this study, high-dose, intraperitoneal 
SVB-treated mice significantly gained body weight 
compared with untreated mice. Inhibition of tumor 
growth may have caused weight gain in this cir-
cumstance, but further investigation is required 
into the mechanism by which this occurred.
Usually a larger spleen is seen when a malfunc-
tioning liver is present. Histopathological studies, 
however, showed no remarkable changes in liver tis-
sues in this study. Interestingly, spleen size was re-
duced in animals treated with intraperitoneal SVB 
(0.5 mg/kg), but the mechanism by which this re-
duction in organ size occurred is unknown. There-
fore further studies are required to fully explain 
this observation.
Mean survival time and ILS were higher in the 
low-dose SVB intraperitoneal treatment group com-
pared with the other treatment groups. Considering 
previous results, we would expect that mean sur-
vival time and ILS would increase in the high-dose 
SVB treatment group, but this was not observed. 
High-dose SVB may have influenced other physiologic 
functions involved in longevity and therefore may 
have influenced mean survival time and ILS. This 
possibility may have in fact been the case, given 
the results of biochemical blood analysis.
Biochemical blood analysis revealed significant 
decrease in phosphatase and urea nitrogen levels 
in animals treated with oral SVB (0.25 mg/kg; p < 
0.01). Additionally, calcium and ALT levels were 
significantly decreased in blood from animals in 
the intraperitoneal SVB (0.5 mg/kg) group (p < 
0.05). Excluding these results, no other significant 
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changes in blood chemistry were observed. These 
findings demonstrate that SVB treatment did not 
cause hepatic malfunction and indicate that other 
physiological process may be affected by SVB 
treatment.
Calcium levels were significantly decreased fol-
lowing intraperitoneal administration of 0.5 mg/kg 
SVB (p < 0.05). However, calcium could be elevated 
with tumor growth, so decreased calcium level 
could indicate that tumor activity was decreased.
Though the results of this study may show that 
SVB has an antitumor effect, similar result pat-
terns were not observed in every experiment. SVB 
treatment may also prevent liver malfunction but 
no dose-dependent action of SVB was seen and 
histo pathological tests showed no visible differ-
ences between control and treated groups. The 
cause of decreased spleen size also needs further 
investigation.
The results of this in vivo study showed that SVB 
may have potential as a tumor growth inhibitor in 
NCI-H460 tumor induced nude mice. Further studies 
to overcome the limitations in the present work are 
needed, as are further investigations into the anti-
tumor mechanism of SVB.
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